Crinetics Pharmaceuticals, Inc. Board of Directors

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. R. Scott Struthers Ph.D.

Dr. R. Scott Struthers Ph.D.

Founder, President, CEO & Director

Mr. Jeff E. Knight

Mr. Jeff E. Knight

Chief Operating Officer

Ms. Adriana Cabre M.B.A.

Ms. Adriana Cabre M.B.A.

Chief Human Resources Officer

Dr. Stephen F. Betz Ph.D.

Dr. Stephen F. Betz Ph.D.

Founder & Chief Scientific Officer

Ms. Garlan Adams

Ms. Garlan Adams

General Counsel & Corporate Secretary

Mr. Marc J. C. Wilson CPA

Mr. Marc J. C. Wilson CPA

Chief Financial Officer

Gayathri Diwakar

Gayathri Diwakar

Head of Investor Relations

Mr. Kevin Capps

Mr. Kevin Capps

Head of Intellectual Property

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.